Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-136692

Published: 2020

Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 396.

https://doi.org/10.1182/blood-2018-99-115930

Published: 2018

Journal Articles

Treatment Patterns and Health/Economic Outcomes in Relapsed/Refractory Follicular Lymphoma: A Real-World Study

Richard van der Jagt, MD FRCPC, Caroline Hamm, MD FRCPC, Isabelle Fleury, MD MSc, FRCP, Véronique Lambert-Obry, M.Sc., Avril Gouault Laliberté, MSc, Alex Castonguay, M.Sc., Dennis Wagner, PhD, Lisa Toltl, PhD, Jean Lachaine, PhD

Blood (2017) 130 (Supplement 1): 5632.

https://doi.org/10.1182/blood.V130.Suppl_1.5632.5632

Published: 2017

Journal Articles

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Brad S Kahl, MD, John M. Burke, MD, Richard van der Jagt, MD FRCPC, Julie Chang, MD, Peter Wood, Tim Hawkins, FRACP, FRCPA, David MacDonald, Judith Trotman, MBChB, FRACP, FRCPA, David Simpson, MBChB, Kathryn S. Kolibaba, MD, Samar Issa, FRACP, Doreen Hallman, Ling Chen, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 484.

https://doi.org/10.1182/blood.V130.Suppl_1.484.484

Published: 2017

Journal Articles

Dyserythropoiesis due to reactive hemophagocytic lymphohistiocytosis

Zhaodong Xu, Richard Van der Jagt

Blood (2016) 128 (17): 2190.

https://doi.org/10.1182/blood-2016-06-722694

Published: 2016

Journal Articles

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke

Blood (2014) 123 (19): 2944–2952.

https://doi.org/10.1182/blood-2013-11-531327

Published: 2014

Includes: Supplemental data

Journal Articles

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

Peter L. Greenberg, Zhuoxin Sun, Kenneth B. Miller, John M. Bennett, Martin S. Tallman, Gordon Dewald, Elisabeth Paietta, Richard van der Jagt, Jessie Houston, Mary L. Thomas, David Cella, Jacob M. Rowe

Blood (2009) 114 (12): 2393–2400.

https://doi.org/10.1182/blood-2009-03-211797

Published: 2009

Includes: Supplemental data

Journal Articles

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Tony Reiman, MD, Daygen Finch, MD, Neil Chua, MD, Darrell White, MD, Douglas A. Stewart, MD, Richard van der Jagt, MD, James Johnston, MD, Angeli Prasad, Henry Schwarz, Jerome Zeldis, MD, Andrew R. Belch, MD

Blood (2007) 110 (11): 2579.

https://doi.org/10.1182/blood.V110.11.2579.2579

Published: 2007

Journal Articles

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Jonathan Friedberg, MD, Philip Cohen, MD, Robert O. Kerr, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Richard van der Jagt, MD, Elber Camacho, MD, John Hainsworth, MD, Brent Roeck, Pratik S. Multani, MD

Blood (2004) 104 (11): 2480.

https://doi.org/10.1182/blood.V104.11.2480.2480

Published: 2004

Journal Articles

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

Kenneth B. Miller, MD, Haesook T. Kim, PhD, Peter Greenberg, MD, Richard van der Jagt, MD, John M. Bennett, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD, Gordon Dewald, PhD, Jessie G. Houston, MD, Mary Thomas, RN, MS, Jacob Rowe, MD

Blood (2004) 104 (11): 70.

https://doi.org/10.1182/blood.V104.11.70.70

Published: 2004

Journal Articles

Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

Blood (1998) 92 (7): 2303–2314.

https://doi.org/10.1182/blood.V92.7.2303

Published: 1998

NARROW

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Treatment Patterns and Health/Economic Outcomes in Relapsed/Refractory Follicular Lymphoma: A Real-World Study

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Dyserythropoiesis due to reactive hemophagocytic lymphohistiocytosis

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only